DelveInsight Report Tracks 30+ TGFb Inhibitor Drugs as Takeda and Hansoh Advance Elritercept

DelveInsight's 2026 TGFb inhibitors report covers 30+ pipeline drugs from 25+ active players, with about 18 in mid and early stages of development. The research firm said in its GlobeNewswire announcement on October 27, 2026, that the pipeline spans anemia, myelofibrosis, glioblastoma, colorectal cancer, pancreatic cancer and other solid tumors.

What DelveInsight's TGFb Report Covers

DelveInsight is a New Delhi-based business consultant and market research firm focused on life sciences, founded in 2014, according to akta.pro company records. The TGFb Inhibitors Pipeline Insight 2026 report profiles clinical strategies, partnering and licensing activity, and regulatory pathways involving the FDA and EMA.

The report lists Takeda and Hansoh Pharma's elritercept (HS-20106) in Phase III for anemia and myelofibrosis, given subcutaneously. Autotelic and Oncotelic Therapeutics' OT-101 is in Phase III for glioblastoma, while MedPacto's oral vactosertib is in Phase II for metastatic colorectal cancer, non-small cell lung cancer, relapsed/refractory multiple myeloma and desmoid tumors.

EpicentRx's AdAPT-001 is in Phase II for sarcoma and refractory solid tumors, Akeso Biopharma's AK130 is in Phase II for pancreatic cancer, and Sirnaomics' STP707 is in Phase I for solid tumors. Arunima Dabral, an associate consultant at DelveInsight, said the field is moving "beyond broad pathway inhibition toward approaches designed to improve target specificity, tissue selectivity, therapeutic window, and clinical tolerability."

Elritercept Milestone and GSK's 35Pharma Deal

Keros Therapeutics said in September 2026 that it expects a $20 million development milestone payment under its elritercept license agreement with Takeda, after the first patient was dosed in the Phase III ELRiSE MF trial. The trial compares elritercept with placebo in myelofibrosis patients with anemia on concurrent ruxolitinib therapy.

In April 2026, GSK completed its acquisition of Canada-based 35Pharma for $950 million, gaining HS235, a candidate for pulmonary hypertension. In July 2025, Keros said the first patient was dosed in the Phase III RENEW trial of elritercept in adults with transfusion-dependent anemia and very low, low or intermediate risk myelodysplastic syndromes, triggering a $10 million milestone payment to Keros under the Takeda license.

DelveInsight's Research Output

DelveInsight has scaled its report repository to more than 7,000 research reports across 27 therapeutic areas, according to the same records. The firm launched DelveEpiAI in March 2026, an AI-powered epidemiology database covering 500+ disease indications with 10-year forecasts across the seven major markets.

The same records list 1,000+ clients across pharmaceutical, biotech and healthcare sectors and 500+ completed consulting projects. DelveInsight released its 2026 Alzheimer's disease competitive landscape report on October 22, 2026, covering more than 240 pipeline drugs from over 200 companies, GlobeNewswire reported.

Earlier TGFb Trial Activity

MedPacto launched a Phase II trial of vactosertib for osteosarcoma in Korea and the U.S. in September 2025, according to the DelveInsight report. Akeso dosed the first patient in its registrational Phase II AK130-202 study in pancreatic cancer the same month.

In November 2025, Tiumbio shared interim Phase II data for Tosposertib (TU2218) combined with MSD's Keytruda as a first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma.